Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb Inks Licensing Deal With Nissan Chemical And Teijin Pharma For Atrial Fibrillation Compound

This article was originally published in PharmAsia News

Executive Summary

Bristol-Myers Squibb signed a licensing agreement with Tokyo-based Nissan Chemical Industries and Teijin Pharma March 4, which gives BMS worldwide rights, excluding Japan, to develop and market atrial fibrillation compound NTC-801, currently in Phase I in Japan
Advertisement

Related Content

Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center in Asia
Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center in Asia
After 10-year Partnership, Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center In Asia
After 10-year Partnership, Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center In Asia
U.S. FDA Clears Takeda Uloric For Gout Indication
U.S. FDA Clears Takeda Uloric For Gout Indication
Advertisement
UsernamePublicRestriction

Register

SC071255

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel